. The prognosis in this condition is even worse than with non-hormone producing oat-cell carcinomas, as high plasma levels of corticosteroids have been claimed to increase tumour growth and spread (Green & Whiteley, 1952; Wolf et al., 1960; Sherlock & Hartmann, 1962) .
Many attempts have been made to treat the associated adrenocortical hyperfunction but with little successs. Metyrapone (SU-4885, 1,2-bis (3 pyridyl)-2 methyl-i propanone, 'metopirone'. Ciba) inhibits the enzyme 1l-3,-hydroxylase, which is essential for the final step in the synthesis of 11 -hydroxycorticosteroids (11-OHCS), of which the most important in man is cortisol (Friedman, Marshall-Jones & Ross, 1966; Meador et al., 1962; Mattingly et al., 1964) . There have been few studies of the value of this drug in treating patients with corticotrophin-secreting tumours (Mattingly et al., 1964; Hugh-Jones, 1964 ; O'Riordan et al., 1966) . O'Riordan et al. (1966) (Mattingly, 1962) at intervals throughout these two periods of treatment with metyrapone (Fig. 1) (Bagshawe, 1960) a hypokalaemic alkalosis was always noted and was thought to be a useful means of distinguishing simple bilateral adrenal hyperplasia from that associated with a corticotrophin-producing malignant tumour. Bagshawe (1960) reported eighteen cases of nonadrenal malignant tumours associated with Cushing's syndrome. All had potassium levels below 3 mEq/l and total CO2 levels between 31 and 52 mEq/l. Alkalosis was not demonstrated in our patient and is not, therefore. an invariable finding in patients with ACTH-secreting tumours. It is possible that the patient may have been catabolizing so much body tissue that she was producing large quantities of acid metabolites which would serve to neutralize the alkalosis usually produced by corticosteroids.
Most authors, including Borstein, Nolan & Bernanke (1961) and O'Riordan et al. 1966) , state that the typical features of Cushing's syndrome occur rarely in the presence of an ACTH-secreting carcinoma, and then only in patients whose tumours grow slowly with relatively moderate production of ACTH. The prognosis is also said to be better in these patients (Bower & Gordan, 1965 (1964) suggested that metyrapone was possibly blocking other enzymes besides 11-/3-hydroxylase.
In the patient described here, the tumour was growing very rapidly and generalized carcinoma-tosis soon became apparent. In selected patients, therefore, and particularly in the slowly growing ACTH producing tumours, which have been previously described (O'Riordan et al., 1966) , metyrapone may be of value in reducing the distressing effects of hyperadrenocorticism. With a rapidly growing tumour metyrapone is probably ineffective and another approach with, for example, aminoglutethimide (Elipten, Ciba) would now be more appropriate.
Granulosa-celi tumour of the ovary causing sexual precocity in a girl aged 31 years General Practitioner, St Germans, Cornwall ACCORDING to Eberlein et al. (1960) isosexual precocity in girls may be arbitrarily defined as the appearance of feminine secondary sexual characteristics before the age of 7 years or menstrual bleeding before the age of 8. The majority of such cases are 'idiopathic' or 'constitutional'; there is a true precocious puberty, gonadotrophins being present and ovulation occurring, and there is no reversal of the early pubertal development. A rare cause of sexual precocity is the presence of functioning ovarian tumours which are usually granulosa-cell or theca-cell tumours. In these cases gonadotrophins are not usually
